Interaction of Positively Charged Oligopeptides with Blood Plasma Proteins

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 11

PMID 36769160

Authors

Aleksandra Kotynia

Aleksandra Marciniak

Wojciech Kamysz

Damian Neubauer

Edward Krzyzak

Affiliations

Soon will be listed here.

Abstract

In this project, we combine two areas of research, experimental characterization and molecular docking studies of the interaction of positively charged oligopeptides with crucial blood plasma proteins. The investigated peptides are rich in NH groups of amino acid side chains from Dap, Orn, Lys, and Arg residues, which are relevant in protein interaction. The peptides are 9- and 11-mer with the following sequences: (Lys-Dab-Dab-Gly-Orn-Pro-His-Lys-Arg-Lys-Dbt), (Lys-Dab-Ala-Gly-Orn-Pro-His-Lys-Arg), and (Lys-Dab-Dab-Gly-Orn-Pro-Phe(2-F)-Lys-Arg). The net charge of the compound strongly depends on the pH environment and it is an important aspect of protein binding. The studied oligopeptides exhibit therapeutic properties: anti-inflammatory activity and the capacity to diminish reactive oxygen species (ROS). Therefore, the mechanism of potential binding with blood plasma components is the next challenge. The binding interaction has been investigated under pseudo-physiological conditions with the main blood plasma proteins: albumin (BSA), α1-acid glycoprotein (AAG), and γ-globulin fraction (GGF). The biomolecular quenching constant (k) and binding constant (K) were obtained by fluorescence spectroscopy at various temperatures. Simultaneously, the changes in the secondary structure of proteins were monitored by circular dichroism (CD) and infrared spectroscopy (IR) by quantity analysis. Moreover, molecular docking studies were conducted to estimate the binding affinity, the binding domain, and the chemical nature of these interactions. The results show that the investigated oligopeptides could be mainly transported by albumin, and the binding domain I is the most favored cavity. The BSA and GGF are able to form stable complexes with the studied compounds as opposed to AAG. The binding reactions are spontaneous processes. The highest binding constants were determined for Lys-Dab-Dab-Gly-Orn-Pro-His-Lys-Arg-Lys-Dbt peptide, in which the values of the binding constants K to BSA and GGF were 10.1 × 10 dmmol and 3.39 × 10 dmmol, respectively. The positively charged surface of peptides participated in salt bridge interaction with proteins; however, hydrogen bonds were also formed. The secondary structure of BSA and GGF after contact with peptides was changed. A reduction in the α-helix structure was observed with an increase in the β-sheet and β-turn and random coil structures.

References

Jiao Q, Wang R, Jiang Y, Liu B . Study on the interaction between active components from traditional Chinese medicine and plasma proteins. Chem Cent J. 2018; 12(1):48. PMC: 5935606. DOI: 10.1186/s13065-018-0417-2. View

Zsila F . Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model. Mol Pharm. 2013; 10(5):1668-82. DOI: 10.1021/mp400027q. View

Ghuman J, Zunszain P, Petitpas I, Bhattacharya A, Otagiri M, Curry S . Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005; 353(1):38-52. DOI: 10.1016/j.jmb.2005.07.075. View

Schley J, Muller-Oerlinghausen B . Investigation of the binding of various tricyclic neuroleptics and antidepressants to alpha 1-acid glycoprotein. J Pharm Pharmacol. 1986; 38(2):102-6. DOI: 10.1111/j.2042-7158.1986.tb04520.x. View

Pernot M, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M . Stability of peptides and therapeutic success in cancer. Expert Opin Drug Metab Toxicol. 2011; 7(7):793-802. DOI: 10.1517/17425255.2011.574126. View

Muller W . Drug binding sites on human alpha-1-acid glycoprotein. Prog Clin Biol Res. 1989; 300:363-78. View

Shi J, Wang F, Liu S . Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep. 2016; 2(1):1-20. PMC: 5071373. DOI: 10.1007/s41048-016-0021-8. View

Curry S, Brick P, Franks N . Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta. 1999; 1441(2-3):131-40. DOI: 10.1016/s1388-1981(99)00148-1. View

Schmid K, Emura J, Schmid M, Stevens R, Nimberg R . Sequence comparison of human plasma alpha1-acid glycoprotein and the immunoglobulins. Int J Pept Protein Res. 1978; 11(1):42-8. DOI: 10.1111/j.1399-3011.1978.tb02819.x. View

10.

Li Y, He W, Liu J, Sheng F, Hu Z, Chen X . Binding of the bioactive component jatrorrhizine to human serum albumin. Biochim Biophys Acta. 2005; 1722(1):15-21. DOI: 10.1016/j.bbagen.2004.11.006. View

11.

Neault J, Tajmir-Riahi H . Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim Biophys Acta. 1998; 1384(1):153-9. DOI: 10.1016/s0167-4838(98)00011-9. View

12.

Majorek K, Porebski P, Dayal A, Zimmerman M, Jablonska K, Stewart A . Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. Mol Immunol. 2012; 52(3-4):174-82. PMC: 3401331. DOI: 10.1016/j.molimm.2012.05.011. View

13.

Szczukowski L, Krzyzak E, Wiatrak B, Jawien P, Marciniak A, Kotynia A . New -Substituted-1,2,4-triazole Derivatives of Pyrrolo[3,4-]pyridazinone with Significant Anti-Inflammatory Activity-Design, Synthesis and Complementary In Vitro, Computational and Spectroscopic Studies. Int J Mol Sci. 2021; 22(20). PMC: 8540742. DOI: 10.3390/ijms222011235. View

14.

Trabi M, Craik D . Circular proteins--no end in sight. Trends Biochem Sci. 2002; 27(3):132-8. DOI: 10.1016/s0968-0004(02)02057-1. View

15.

Wedemayer G, Patten P, Wang L, Schultz P, Stevens R . Structural insights into the evolution of an antibody combining site. Science. 1997; 276(5319):1665-9. DOI: 10.1126/science.276.5319.1665. View

16.

Quinones-Mateu M, Schols D . Virus-inhibitory peptide: a natural HIV entry inhibitor in search for a formal target in the viral genome. AIDS. 2011; 25(13):1663-4. DOI: 10.1097/QAD.0b013e32834a36ea. View

17.

Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K . Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 1999; 12(6):439-46. DOI: 10.1093/protein/12.6.439. View

18.

Otagiri M . A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet. 2005; 20(5):309-23. DOI: 10.2133/dmpk.20.309. View

19.

Latham P . Therapeutic peptides revisited. Nat Biotechnol. 1999; 17(8):755-7. DOI: 10.1038/11686. View

20.

Hadichegeni S, Goliaei B, Taghizadeh M, Davoodmanesh S, Taghavi F, Hashemi M . Characterization of the interaction between human serum albumin and diazinon via spectroscopic and molecular docking methods. Hum Exp Toxicol. 2018; 37(9):959-971. DOI: 10.1177/0960327117741752. View